STOCK TITAN

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Kyverna Therapeutics (Nasdaq: KYTX), a clinical-stage biopharmaceutical company specializing in cell therapies for autoimmune diseases, has announced its upcoming participation in the Leerink Partners Global Biopharma Conference.

The company's CEO, Warner Biddle, is scheduled to present at the conference in Miami, FL on Monday, March 10, 2025, at 3:00 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the Investors section of Kyverna's website at ir.kyvernatx.com. The presentation recording will remain available for replay on the website for 30 days after the conference.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction

+1.54%
1 alert
+1.54% News Effect

On the day this news was published, KYTX gained 1.54%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

EMERYVILLE, Calif., March 3, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Leerink Partners Global Biopharma Conference in Miami, FL on Monday, March 10, 2025, at 3:00 p.m. ET.

A live webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for 30 days following the conference.

About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase 2 trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis. Kyverna is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for it to advance into late-stage development. Its pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. For more information, please visit https://kyvernatx.com.

Contact:
Investors: InvestorRelations@kyvernatx.com 
Media: media@kyvernatx.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-to-present-at-the-leerink-partners-global-biopharma-conference-302390580.html

SOURCE Kyverna Therapeutics

FAQ

When is Kyverna Therapeutics (KYTX) presenting at the Leerink Partners Conference 2025?

Kyverna Therapeutics will present on Monday, March 10, 2025, at 3:00 p.m. ET in Miami, FL.

How can investors watch Kyverna's (KYTX) Leerink Partners Conference presentation?

Investors can watch the live webcast through Kyverna's investor relations website at ir.kyvernatx.com.

How long will Kyverna's (KYTX) Leerink Conference presentation be available for replay?

The presentation webcast will be available for replay on Kyverna's website for 30 days following the conference.

What is the main focus of Kyverna Therapeutics (KYTX)?

Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases.
Kyverna Therapeutics

NASDAQ:KYTX

KYTX Rankings

KYTX Latest News

KYTX Latest SEC Filings

KYTX Stock Data

432.74M
43.80M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
EMERYVILLE